Skip to main content
Signal8

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

$NWBOPress releaseJul 2, 2026, 2:42 PM ET

Northwest Biotherapeutics announced that CTO Dr. Marnix Bosch will present data at the British Neuro-Oncology Society meeting showing DCVax-L survival extension using propensity score matching. The presentation focuses on the 331-patient Phase III trial for glioblastoma, for which a Marketing Authorization Application is currently under review in the UK.

Key figures

Drug Name
DCVax-L
Maa Status
under review
Patient Count
331
Phase Of Trial
Phase III
Presentation Title
DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.